Overview
CMND market data
Price History
CMND price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$303.46 Diluted earnings per share over the trailing twelve months.
- Beta
- 20.10 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.43 – $524.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.7M · P/B 1.81.
Company News
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment TrialBenzinga · Aug 13, 2026, 6:05 PM
Clearmind Medicine Says DSMB Unanimously Approved Advancing Phase 1/2 Trial Of CMND-100 To Parts B And C In Alcohol Use Disorder Patients And Healthy ParticipantsBenzinga · Aug 13, 2026, 11:36 AM
Clearmind Medicine Says Permeation Study Shows Intranasal MEAI Reached 97.35% Cumulative Permeation At 180 Minutes vs. 98.34% For Conventional FormulationBenzinga · Aug 11, 2026, 12:09 PM
Clearmind Medicine Announces DSMB Approval To Advance Phase 1/2 Trial Of CMND-100 Into Parts B And C, Marking First Dosing In Alcohol Use Disorder PatientsBenzinga · Aug 6, 2026, 12:17 PM
Clearmind Medicine shares are trading lower after the company signed a non-binding LoI to acquire a 51% stake in a company making intelligent EV wireless charging solutions for automated parking systems and autonomous mobile platforms.Benzinga · Aug 3, 2026, 1:22 PM
Clearmind Medicine Announces Non-Binding Letter Of Intent To Acquire 51% Stake In Unnamed EV Wireless Charging Company For $2.5M Plus $1.5M Loan At 4% InterestBenzinga · Aug 3, 2026, 12:07 PM
Clearmind Medicine Announces Safety Results From Part A Of Its Ongoing FDA-regulated Phase I/II Clinical Trial Evaluating CMND-100; All 24 Participants Enrolled Across Four Ascending-Dose Cohorts Successfully Completed TreatmentBenzinga · Jul 30, 2026, 12:32 PM
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II TrialGlobenewswire Inc · Jul 28, 2026, 12:15 PM
Clearmind Medicine Completes Treatment For All Participants In Part A Of Its Ongoing Phase I/II Clinical Trial Evaluating CMND-100 For Alcohol Use DisorderBenzinga · Jul 28, 2026, 11:49 AM
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics MarketGlobenewswire Inc · Jul 20, 2026, 1:00 PM